ImageneBio expands IMG-007 dosing regimens after March safety review, targets 2027 readout
ImageneBio’s IMG-007 Phase 2b ADAPTIVE trial in moderate-to-severe atopic dermatitis has enrolled North American patients, with a March 2026 blinded safety review confirming favorable tolerability and no T-cell depletion-linked adverse events. The company submitted a protocol amendment expanding dosing regimens and expects topline data in 2027.
1. Financial Results and Corporate Financing
ImageneBio reported its fourth quarter and full year 2025 financial results, concluding the year ended December 31, 2025, and reaffirmed its corporate structure following its July 2025 reverse merger with Ikena Oncology and a concurrent $75 million private placement. The transaction furnished capital to advance the IMG-007 development program and support operational growth.
2. IMG-007 Phase 2b ADAPTIVE Trial Progress
IMG-007, a non-T cell-depleting anti-OX40 monoclonal antibody, is being evaluated in the Phase 2b ADAPTIVE trial in adults with moderate-to-severe atopic dermatitis at North American sites. A blinded safety review in March 2026 confirmed a favorable tolerability profile with no treatment-related serious adverse events and less than 0.10% mild injection site reactions, and a protocol amendment was submitted to expand dosing regimens, loading doses and patient-friendly intervals ahead of a 2027 topline readout.
3. Executive Appointment and Scientific Presentation
In February 2026, Dr. Ben Porter-Brown joined as Chief Medical Officer, bringing over 20 years of autoimmune and dermatology development experience. An oral presentation of IMG-007’s preclinical non-depleting profile is scheduled for the Society for Investigative Dermatology Meeting in May 2026 in Chicago.